PITTSBURGH--(BUSINESS WIRE)--Helomics Corporation (formerly Precision Therapeutics), a privately held comprehensive personalized healthcare company that develops innovative next generation diagnostics for the oncology field, announced today that the Company is scheduled to present at the Biotech Showcase™ 2015 taking place in San Francisco, CA on January 12-14, 2015.
Neil Campbell, President and Chief Executive Officer of Helomics, will provide an overview of the Company’s business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings with management may also be scheduled outside of Biotech Showcase by contacting Helomics’ investor relations.
|
Event: |
Biotech Showcase™ 2015 |
||||||||||
|
Date: |
Tuesday, January 13, 2015 | ||||||||||
|
Time: |
1:45pm (Pacific Time) | ||||||||||
|
Location: |
Parc 55 Wyndham, San Francisco, CA | ||||||||||
About Biotech Showcase 2015
Biotech Showcase™ is an investor
and partnering conference devoted to providing private and public
biotechnology and life sciences companies with an opportunity to present
to, and meet with, investors and pharmaceutical executives in one place
during the course of one of the industry's largest annual healthcare
investor conferences. Investors and biopharmaceutical executives from
around the world gather in San Francisco during this critical week,
which is widely viewed as setting the tone for the coming year.
About Helomics™ Corporation
Helomics is a comprehensive
personalized healthcare company, bringing the next generation of
diagnostics to the oncology field. Helomics is dedicated to improving
patient outcomes by utilizing a proprietary set of laboratory platforms
and our product science as a service commercialization model to allow
physicians to characterize malignant tumors. Helomics’ novel molecular
and cellular markers and bioinformatics services are designed to support
treatment decisions by providing vital information based on the specific
biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.